Retrospective Study Of Treating In Chronic Renal Failure With Urokinase

Objective:To retrospectively analyze the clinical data of patients with chronic renal failure(CRF)who were treated with urokinase in Guangzhou General Hospital of Guangzhou Military Command in recent 10 years,to summarize the clinical experiences and evaluate the efficacy and safety,and to expand the clinical application of urokinase.Methods:Clinical data of 99 CRF patients treated from Feb 2006 to Feb 2016 in Nephrology Department in Guangzhou General Hospital of Guangzhou Military Command were collected.The changes of BUN,SCr,Ccr,24h-UTP,ALT and AST were observed in the 50 observation group and 49 control group before and after treatment,the efficacy and safety of urokinase in the treatment of CRF patients were evaluated.Results:1.Total effective rate of clinical efficacy in observation group was better than that in control group,the difference between the two groups was statistically significant(P <0.01).2.After the treatment,the observation indexes(Scr,Ccr,BUN,24h-UTP)in two groups were all better than those before treatment(P <0.01);At the same timepoint after treatment,the improvement of Scr,Ccr and BUN in observation group were better than those in control group(P <0.01),but there was no statistical difference of 24h-UTP between two groups(P >0.05).3.There were no significant differences between two groups in the incidence of adverse reactions and liver function before and after treatment(P >0.05).Conclusions:1.Compared to the fundamental therapy,additional use of urokinase could further decrease levels of Scr and BUN,increase levels of Ccr,which delay the progress of renal failure more obviously.2.It is safe to treat CRF patients with urokinase due to its low incidence of adverse reactions and no effect on liver function.